<DOC>
	<DOCNO>NCT01515306</DOCNO>
	<brief_summary>The purpose study investigate whether clinically significant pharmacokinetic effect concomitant ramucirumab ( IMC-1121B ) paclitaxel investigate pharmacokinetics ( PK ) participant advance malignant solid tumor . Part A study investigate potential concomitant ramucirumab ( IMC-1121B ) affect pharmacokinetics paclitaxel . Part B study investigate pharmacokinetics ramucirumab ( IMC-1121B ) monotherapy .</brief_summary>
	<brief_title>A Study Ramucirumab ( IMC-1121B ) Paclitaxel Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Has histologic cytologic documentation malignant solid tumor Has advance solid tumor refractory standard therapy standard therapy available Part A : Has 01 prior taxanecontaining treatment regimen ( include taxane monotherapy ) , must complete least 6 month first dose study medication ( prior bevacizumab allow ) Part B : Prior bevacizumab taxanecontaining treatment regimen ( include taxane monotherapy ) allow , provide regimen complete least 6 month first dose study medication Has resolution Grade ≤ 1 clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy exception peripheral neuropathy , must exceed Grade 1 , National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 ( NCICTCAE v 4.0 ) Has Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 2 Has adequate hematologic function . Blood transfusion allow must complete 48 hour study drug administration Has adequate hepatic function ( bilirubin ≤ 1.5 time upper limit normal [ ULN ] , aspartate transaminase [ AST ] alanine transaminase [ ALT ] ≤ 1.5 x ULN Has serum creatinine ≤ 1.5 x ULN . If serum creatinine &gt; 1.5 x ULN , calculate creatinine clearance ( CrCl ) ≥ 40 milliliter/minute ( mL/min ) Urinary protein &lt; 2+ dipstick routine urinalysis ( UA ) Must adequate coagulation function define international normalized ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) activate PTT ( aPTT ) ≤ 1.5 x ULN Eligible participant reproductive potential agree use adequate method contraception study period 12 week last dose study medication Is receive concomitant therapy clinically relevant inhibitor inducer cytochrome P450 , CYP2C8 , CYP3AY and/or isoenzymes Are currently enrol , discontinue within last 14 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Has receive monoclonal antibody within 42 day prior first dose study medication Has receive radiotherapy within 14 day prior first dose study medication Has receive cytotoxic chemotherapy within 21 day ( 6 week nitrosoureas mitomycin C ) prior first dose study medication Has cardiac leave ventricular ejection fraction ( LVEF ) within institutional limit normal multigated acquisition scan ( MUGA ) echocardiogram Is receive concurrent treatment another anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiation therapy , chemoembolization , target investigational anticancer therapy Is receive chronic therapy nonsteroidal antiinflammatory agent antiplatelet agent . Aspirin use dose 325 milligrams/day ( mg/day ) analgesic agent low bleed risk permit Has history uncontrolled hereditary acquire bleed thromboembolic disorder Has experience arterial thromboembolic event , include myocardial infarction ( MI ) , unstable angina stroke transient ischemic attack ( TIA ) , within 6 month prior first dose study medication Has history deep vein thrombosis , pulmonary embolism , significant thromboembolism 3 month prior first dose study medication Has experience Grade 3 4 hemorrhagic event within 3 month prior first dose study medication Has experience peripheral neuropathy ≥ Grade 2 time prior study entry Has bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection , Crohn 's disease , ulcerative colitis , chronic diarrhea History gastrointestinal perforation / fistula within 6 month prior randomization Has ongoing active infection require treatment intravenous antibiotic Has serious nonhealing wound , peptic ulcer , bone fracture within 28 day prior first dose study medication Has uncontrolled hypertension Has symptomatic congestive heart failure Has know brain leptomeningeal disease Has know positive status human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndromerelated illness Has know active drug alcohol abuse would affect participant 's ability comply study treatment Has pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen Has major surgery within 28 day prior first dose study medication subcutaneous venous access device implantation within 7 day prior first dose study medication Has elective plan major surgery course trial If primary cancer nonsmallcell lung cancer ( NSCLC ) , participant intratumor cavitation , radiologically document evidence major blood vessel invasion encasement cancer , proximity cancer major airway Has receive prior ramucirumab ( IMC1121B ) therapy The participant : cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Malignant Solid Tumors</keyword>
</DOC>